Here is a detailed accounting of the most consequential insider trading activity recorded for Monday, June 1, 2026, across U.S. public equities. The day featured a mix of large insider-led purchases and several substantial sell-side events, involving directors, affiliated investment vehicles, and private funds. The transactions covered companies in biotech, healthcare equipment, energy and cloud software.
Significant purchases
Q32 Bio Inc. (NASDAQ: QTTB) registered two simultaneous private placement purchases that together amounted to $30.0 million. On May 28, 2026, director and 10% owner Xu Diyong bought 1,875,000 shares at $8.00 each, for a $15.0 million total. At the same price and on the same date, a consortium of OrbiMed entities - OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC - acquired an additional 1,875,000 shares for another $15.0 million. The combined purchases were executed as private placement transactions. Q32 Bio shares have climbed 537% over the past 12 months and were trading at $11.66 at the time the reporting highlighted the trades, marking a 46% premium to the $8.00 placement price. InvestingPro analysis referenced in the filings suggests the stock is trading above its Fair Value estimate.
Outlook Therapeutics, Inc. (NASDAQ: OTLK) also saw a sizeable insider-affiliated purchase. GMS Ventures & Investments - an entity tied to director Ghiath M. Sukhtian - acquired 8,539,709 shares of common stock at a per-share price of $0.5855 on May 28, 2026. The transaction was structured as a registered direct offering and amounted to roughly $5.0 million. After the purchase, GMS Ventures & Investments reported direct ownership of 22,092,068 shares of Outlook Therapeutics common stock.
In the energy sector, Vitesse Energy, Inc. (NASDAQ: VTS) reported a direct purchase by director Joseph S. Steinberg. On May 28, 2026, Mr. Steinberg bought 59,118 shares at $17.00 per share for a total cash outlay of $1,005,006. Following the trade, he directly held 60,552 shares of company common stock. The transaction occurred while the stock was trading near its 52-week low - reported as $16.91 - and the shares were later noted at $17.73. InvestingPro analysis cited in the reports indicates Vitesse Energy appears undervalued relative to its Fair Value and that the company offers an approximate 10% dividend yield.
Boston Omaha Corp. (NASDAQ: BOC) director Frank H. Kenan II increased his position through multiple purchases spanning May 28 to June 1, 2026, totaling about $671,249. The aggregate transaction comprised 50,752 shares of Class A common stock purchased in tranches at prices between $12.89 and $13.3697 per share. Specifically, on May 28, 2026, he acquired 34,719 shares at an average price of $13.3697, with individual trades ranging from $13.13 to $13.43. On May 29, he added 10,000 shares at an average price of $12.93, with execution prices between $12.89 and $12.99. The final reported buy on June 1, 2026, was 6,033 shares at $12.89 per share. Boston Omaha shares were trading at $13.09 in the period noted, down 8% over the prior year but up nearly 6% year-to-date. InvestingPro analysis included with the filings suggests the company appears overvalued on a Fair Value basis at current prices.
Major disposals
The largest insider sale by dollar value was a block offering by funds affiliated with Hellman & Friedman at Medline Inc. (MDLN). On May 28, 2026, the group sold 31,868,237 shares of Class A Common Stock in an underwritten public offering at an effective price of $36.5375 per share, producing proceeds of roughly $1.16 billion. The per-share figure represents the public offering price of $37.00 less an underwriting discount of $0.4625 per share. The offering price was reported as a premium to the prevailing market price at the time of the trade. InvestingPro analysis cited in the filings nonetheless indicates Medline was trading below its Fair Value, implying the company may be undervalued on the valuation metric referenced.
Illumina, Inc. (NASDAQ: ILMN) director Keith A. Meister disclosed a series of indirect sales through private funds known as the Corvex Funds. Between May 28 and June 1, 2026, Mr. Meister sold 671,696 shares of Illumina common stock at prices ranging from $147.50 to $165.50 per share, for total proceeds of about $107.04 million. The filings indicate the dispositions were executed indirectly via investment funds. Illumina shares were trading at $164.72 in the reporting window and were noted to be near their 52-week high, having posted a 90% gain over the previous year.
Taboola.com Ltd. (NASDAQ: TBLA) recorded a significant open-market sale on May 28, 2026. Apollo Management Holdings GP, LLC and affiliated Apollo entities reported that College Top Holdings, Inc. sold 12,000,000 non-voting ordinary shares at $4.40 each, producing approximately $52.8 million of proceeds. College Top Holdings is described in the filings as holding Taboola securities on behalf of Yahoo Inc., its indirect wholly owned subsidiary. The broader Apollo-related reporting entities disclaimed beneficial ownership beyond any pecuniary interest. Taboola shares have since risen to $4.95, trading close to a 52-week high of $5.26 and carrying a market capitalization of $1.33 billion in the disclosure period.
Snowflake Inc. (NYSE: SNOW) reported director-led sales and option exercises on May 29, 2026. Director Mark Garrett sold 100,000 shares at a weighted-average price of $250.002 per share, for a total of $25,000,200. Individual trades ranged from $250.000 to $250.170 per share. On the same day, Mr. Garrett also exercised a fully vested stock option to acquire 100,000 shares at $3.74 per share, amounting to $374,000 in option exercise proceeds. The reported option in Mr. Garrett’s filing is scheduled to expire on April 14, 2028. Director Frank Slootman disclosed the exercise of fully vested options and subsequent sales executed under a pre-arranged trading plan; his option exercise covered 437,076 shares at an $8.88 exercise price, with the exercise amounting to $3,881,234 in total. Snowflake shares subsequently rose to $279.96 in the reporting window, delivering a 62.7% return over the prior week and trading near a 52-week high of $284.99. InvestingPro commentary included with the filings indicates Snowflake appears overvalued relative to its Fair Value estimate.
Context and considerations
Monitoring insider transactions offers investors an additional data point on how company insiders and affiliated investors are positioning around corporate equities. Purchases by directors or investment vehicles tied to board members can signal conviction in the issuer’s near-term prospects, while large fund sales or underwritten offerings can reflect liquidity events, portfolio rebalancing or other institutional priorities. The filings in this batch of transactions include private placements, registered direct offerings, underwritten public offerings and open market trades, illustrating a range of execution mechanisms used by insiders and affiliated entities.
It is important to recognize limits inherent to any single dataset. Insider sales may be driven by personal financial planning, tax obligations or other considerations unrelated to company fundamentals. Conversely, insider purchases, even when sizeable, may be part of negotiated private placements or other strategic financings. The accompanying InvestingPro analysis cited in these reports offers valuation context - indicating some securities in this set appear overvalued and others undervalued relative to Fair Value estimates - but those assessments are one input among many for investors conducting fundamental research.
What to watch next
- Biotech investors may follow Q32 Bio’s post-placement price trajectory and any subsequent disclosures tied to the private placements.
- Stake increases by directors at Outlook Therapeutics and Boston Omaha will be of interest to holders tracking board-aligned capital commitments.
- Large-scale institutional offerings, such as the Hellman & Friedman-led Medline sale, underscore potential shifts in ownership structure and liquidity that investors should factor into valuations.